Laser-based lab equipment maker Hamilton Thorne Inc. (TSX-V: HTL) has named company president David Wolf as CEO. Wolf takes over the post from company co-founder Meg Spencer, who will remain with Hamilton Thorne as chairman of the board and a chief strategic advisor.
Wolf, who helped take the company public, has been president of the Hamilton Thorne since 2009 and will continue to hold that role along with the additional CEO responsibilities.
"David has played a key role in developing and implementing the Company’s growth and financing strategies over the last two years, and I know that he is the right person to take Hamilton Thorne into its next phase of development," said Spencer in a prepared statement.
In addition to his new corner office, Wolf has been appointed to the board of directors and granted incentive stock options to purchase common shares of the company.
Last week, Hamilton Thorne closed a private placement of common shares with gross proceeds of $2.55 million.
Here’s the latest personnel changes from medical device, diagnostics and life science companies around the nation. For more recent hirings and firings, check out MassDevice’s compilation of the latest personnel moves.
- SyberMed Enterprises has a new name and a new CEO
Intravenous device company, SyberMed Enterprises has changed their name to Linebacker. The name change, reflecting the company’s product rather than their founder, isn’t the only big change. Linebacker also hired Roche Diagnostics veteran Jack Kromar as its new CEO, replacing company founder Dr. David Sybert.
- Covidien executive named Cornerstone Therapeutics new president
Cary, N.C.-based respiratory therapeutics company Cornerstone Therapeutics (NASDAQ:CRTX) named former Covidien executive Kenneth McBean president. McBean started his new job earlier this week and will report to Cornerstone chairman and CEO Craig Collard.
- DaVita Inc names executives to spearhead international expansion
Denver, Co.-based DaVita Inc. (NYSE:DVA) named executives Atul Mathur and Björn Englund to lead their international expansion efforts. Initial expansion is planned in both European and Asia-Pacific regions. DaVita is focused on developing medical devises relating to kidney care.